Boston Scientific Corporation
) has begun the year on a good note. The company kick-started the
year with the launch of OffRoad Re-Entry Catheter System in the
U.S and receipt of a CE mark in Europe for its WallFlex
Esophageal Stent in February. Thereafter, Boston Scientific
obtained the CE mark for its REBEL Platinum Chromium
Coronary Stent System and Ingevity MRI Pacing Leads in March.
Recently, Boston Scientific won U.S. Food and Drug
Administration (FDA) and CE mark approval for the Expect Slimline
(SL) Needle. The product, which has been launched globally, will
be used for Endoscopic Ultrasound-Fine Needle Aspiration
The EUS-FNA procedure is an advanced and time-saving way to
conduct a tissue biopsy. The Expect Slimline Needle is used to
collect tissue samples which are examined through EUS-FNA
procedures from organs close to the gastrointestinal tract. The
procedure is associated with improved survival rates in patients
suffering from pancreatic cancer as it allows healthcare
providers to make more informed therapeutic decisions.
The launch of the Expect Slimline Needle, whose design is
exclusively based upon customer feedbacks, seems to be well
aligned with one of Boston Scientific's key strategic initiatives
of developing vital capabilities by delivering customer-focused
and economical products.
The Expect Slimline Needle comes under Boston Scientific's
Endoscopy business and focuses on gastrointestinal endoscopy. In
2013, Boston Scientific generated 18% of its total revenue from
the Endoscopy business. With MarketsAndMarkets estimating global
endoscopic markets to grow to $37.9 billion by 2018 and at a
compounded annual growth rate (CAGR) of 6.1% from 2013 to 2018,
we believe Boston Scientific will experience accelerated revenues
from its Endoscopy business.
However, similar products are available in the market
including Cook Medical's Spirotome Soft-Tissue Biopsy Needle Set.
At present, we would like to remain on the sidelines and wait
until more visibility is obtained about the performance and
demand for Boston Scientific's Expect Slimline Needle.
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader healthcare industry are
St. Jude Medical Inc.
).Enzymotec sports a Zacks Rank #1 (Strong Buy) while St. Jude
Medical and Covidien carry a Zacks Rank #2 (Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
ENZYMOTEC LTD (ENZY): Free Stock Analysis
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.